<DOC>
	<DOCNO>NCT00003209</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell . It yet know whether give radiation therapy chemotherapy surgery effective radiation therapy alone surgery treat cervical cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without chemotherapy surgery treat patient stage IB stage IIA cervical cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy After Surgery Treating Patients With Stage IB Stage IIA Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare relapse free overall survival radiation therapy without sequential use chemotherapy patient node positive stage IB IIA cervical cancer . II . Compare toxic effect two treatment patient population . III . Study effect addition chemotherapy pattern relapse patient . OUTLINE : This randomize , multicenter study . Patients stratify accord institution , stage , site lymph node involvement , parametrial invasion , resection margin status , diameter primary lesion , preoperative brachtherapy . Patients assign one two treatment arm begin therapy within 6 week surgery . Arm I : Patients receive radiation therapy pelvis without brachytherapy and/or para-aortic irradiation 4-5 week . Arm II : Patients receive radiation therapy arm I plus 1 5 different cisplatin-based combination chemotherapy regimens . The patient preferably receive chemotherapy radiation therapy , unless doubtful positive margin present , radiation therapy give first . Regimen I : Cisplatin fluorouracil administer day 1 2 21 day cycle . Patients receive 4 cycle therapy . Regimen II : Bleomycin administer day 1 cisplatin ifosfamide administer day 2 21 day cycle . Patients receive 4 cycle therapy . The regimen may also give without bleomycin . Regimen III : Patients receive vindesine day 1 8 , cisplatin day 1 , bleomycin day 2-4 , mitomycin day 5 ( cycle 1 3 ) . Each cycle last 21 day patient receive 4 cycle therapy . Regimen IV : Cisplatin vinblastine administer day 1 bleomycin administer day 1 , 8 , 15 21 day cycle . Each patient receive 4 cycle therapy . Regimen V : Patients receive cisplatin methotrexate day 1 14 day cycle . Patients receive 6 cycle therapy . Patients follow every 3 month first 2 year , every 6 month next 3 year , annually next 5 year . PROJECTED ACCRUAL : Approximately 700 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IB IIA cervical cancer Squamous cell carcinoma Adenosquamous cell carcinoma Adenocarcinoma Pelvic and/or common iliac paraaortic lymph node involvement Undergone radical hysterectomy , complete pelvic lymphadenectomy , resection enlarge common iliac paraaortic lymph nod No clear cell carcinoma small cell carcinoma neuroendocrine differentiation Resectable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 14.6 mg/dL Renal : Creatinine great 1.356 mg/dL Creatinine clearance least 60 mL/min Pulmonary : Maximum breathing capacity least 30 L/min FEV1 least 1.0 L No sign respiratory insufficiency Other : No potentially active site infection ( e.g. , fistula abscess ) No prior concurrent second malignancy except adequately treat basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No preoperative external radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>